Swiss upper house votes in favor of UBS backing foreign units with 90% CET1 capital – report (UBS:NYSE)September 23, 2026
Share Facebook Twitter LinkedIn Pinterest Email Spero Therapeutics GAAP EPS of $0.96 beats by $1.06, revenue of $73.5M beats by $54.87M
Swiss upper house votes in favor of UBS backing foreign units with 90% CET1 capital – report (UBS:NYSE)September 23, 2026
By Press Room
By Press Room
By Press Room
